Amgen announces results from AMG 334 study for the prevention of episodic migraine

Amgen last week announced the first results from its global Phase 2, double-blind, placebo-controlled study that assesses the efficiency and safety of AMG 334 for the prevention of episodic migraine.

The study met its main endpoint, which was to reduce monthly mean migraine days compared with placebo.

AMG 334 is a fully human monoclonal antibody under investigation to prevent migraines by stopping the calcitonin gene-related peptide receptor thought to transmit signals that can cause debilitating pain.

"Migraine is a complicated, underdiagnosed neurological condition that has significant impact on the everyday activities of those who live with it, and for the millions of people around the world who are affected by this disease, significant unmet therapeutic need persists," Sean Harper, executive vice president, research and development at Amgen, said. "We are encouraged by these Phase 2 data, which further validate AMG 334 as a potential preventive treatment for episodic migraine."

Secondary study endpoints included a 50 percent responder rate, monthly migraine attacks and safety and tolerability. AMG 334 showed a statistically significant increase in the 50 percent responder rate compared with placebo. Decreases in monthly headache days and monthly migraine-specific medication use days were statistically significant in patients taking the AMG 334 dose.

The data from the study were presented at the 17th Congress of the International Headache Society in Valencia, Spain.